Shots:

• The US FDA BT’s designation is based on P-II study assessing the impact of Orencia on the prevention of severe acute GvHD when added to a standard GvHD prophylactic regimen in patients with hematologic malignancies receiving a stem cell transplant from an unrelated- HLA-matched or mismatched donor
• A BT designation is granted to expedite the development and regulatory review of an investigational medicine that is intended to treat a serious or life-threatening condition
• Orencia is an immunomodulator targeting proteins involved in co-stimulation- thus inhibiting T-cell activation and is an approved therapy to treat multiple RA conditions. If approved by FDA- Orencia will be the first approved therapy to prevent acute GvHD

Click here to­ read full press release/ article 

Ref: BMS | Image: BMS